As shown in Figure 4B, treatment of prostate cancer cells with ATR II (0, 50 and 100 μM) for 12 h inhibited the STAT3 and promoter activity reached up to 70 and 40% in DU145, whereas LNCaP was reached up to 60 and 12% compared to control. This evidence concerns the gene STAT3 and Familial prostate cancer.